KAS
SGMT icon

Kestra Advisory Services’s Sagimet Biosciences SGMT Stock Holding History

Kestra Advisory Services’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$513K Hold
66,414
– – ﹤0.01% 2327
2026
Q1 		$347K Buy
66,414
+400
+0.6% +$2.23K ﹤0.01% 2503
2025
Q4 		$391K Buy
+66,014
New +$474K ﹤0.01% 2331

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Kestra Advisory Services's SGMT Position: Q2 2026 in Review

Kestra Advisory Services held its Sagimet Biosciences (SGMT) position steady in Q2 2026 at 66,414 shares worth $513K. The position accounts for ﹤0.01% of the portfolio, ranked #2327.

Kestra Advisory Services first reported a position in SGMT in Q4 2025 and has held it in 3 quarters since. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Kestra Advisory Services held 66,414 shares of Sagimet Biosciences worth $513K as of Q2 2026.
  • Kestra Advisory Services left its Sagimet Biosciences share count unchanged in Q2 2026.
  • Sagimet Biosciences made up ﹤0.01% of Kestra Advisory Services's portfolio in Q2 2026, its #2327 holding.
  • Kestra Advisory Services first reported a position in Sagimet Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Kestra Advisory Services's 13F filing for Q2 2026, filed 28 Jul 2026.